Bathroom Reading
A newly approved anti-diarrheal agent seeks to counter side effects of HAART
by Chael Needle
Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...
Year in Review
What were the top five HCV-related stories of 2012?
by Larry Buhl
There were many important news stories about hepatitis in 2012. In this column we...
Flipping the Script
Walgreens dispenses vital support through HIV-specialized pharmacies
Wellness Watch by Chael Needle
Individuals living with HIV/AIDS and in treatment may not know that one pharmacy may...
Starting the Conversation
HEPCredefined.com provides a portal for learning about HCV
Hep Talk by Larry Buhl
It’s been said that the hepatitis C virus (HCV) is a silent killer,...
Monoclonal Antibodies
Stronger Punch?
Monoclonal antibodies provide new hope for easier dosing
by Jeannie Wraight
With multi-drug, once-a-day therapies now available for use, the push for additional easier to...
TB Announced
A not-for-profit biotech helps energize the future of TB vaccine R&D
by Chael Needle
According to the World Health Organization, tuberculosis is the most common illness...
UFO Plan Meets IDUs
Finger on the Pulse
The UFO Plan meets young IV drug users where they are
by Larry Buhl
Hepatitis prevention and treatment efforts depend on outreach. For...
Alisson Sombredero, MD
Not So Complicated
Alisson Sombredero, MD, offers to physicians compelling approaches to HIV care
by Chael Needle
Alisson Sombredero, MD, is more than two months into her...
New Generation DDAs
Six drugs promise to further revolutionize HCV treatments
by Larry Buhl
The hepatitis C (HCV) treatment revolution is a little more than a year old, but...
Don’t Fear the Treatment
HCV advocate, author & nurse Lucinda Porter offers perspectives on care
by Larry Buhl
Lucinda Porter, RN, understands viral hepatitis from both sides: as a healthcare practitioner and...